Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial

14. november 2026 opdateret af: Xuekui Liu

A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).

The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes.

Participants will be randomly assigned in a 1:1 ratio to one of two groups:

Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy.

Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy.

After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin.

The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Background:

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy worldwide. For locally advanced resectable HNSCC, the standard treatment paradigm often involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. However, the 5-year survival rate remains suboptimal, and the optimal neoadjuvant regimen is still debated. Immunotherapy, particularly PD-1 inhibitors, has shown promising efficacy in recurrent/metastatic HNSCC. Our previous Phase II trial demonstrated that neoadjuvant Camrelizumab combined with nab-paclitaxel and cisplatin was safe and highly effective (Objective Response Rate of 89.6%). This Phase III study is designed to further validate these findings.

Study Design:

This is a randomized, open-label, multicenter, Phase III clinical trial. A total of 212 eligible patients with clinical stage III-IV (T2N2-3M0, T3-4N0-3M0, AJCC 8th) resectable HNSCC will be enrolled and randomized 1:1 to the experimental or control group.

Interventions:

Experimental Arm: Neoadjuvant Camrelizumab (200 mg, IV, Day 1) + nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles (21-day cycle).

Control Arm: Neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles.

After 3 cycles, tumor response will be evaluated per RECIST v1.1. Patients with oropharyngeal, laryngeal, or hypopharyngeal cancer who achieve CR/PR and wish to preserve organ function will receive radical radiotherapy plus cisplatin; those with residual disease will undergo salvage surgery. Other patients will undergo radical surgery with organ preservation. Adjuvant therapy will be administered based on NCCN/CSCO guidelines and multidisciplinary team discussion.

Outcomes:

The primary endpoint is 2-year Event-Free Survival (EFS). Secondary endpoints include 2-year Overall Survival (OS), 2-year Progression-Free Survival (PFS), organ preservation rate, Disease Control Rate (DCR), Objective Response Rate (ORR), safety, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and exploratory biomarker analysis (PD-L1 CPS, TMB, etc.).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

212

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 1. Histologically and/or cytologically confirmed, previously untreated head and neck squamous cell carcinoma (diagnostic treatment excluded).

    2. Clinical stage T2N2-3M0 or T3-4N0-3M0 (Stage III-IV, AJCC 8th edition). 3. Age between 18 and 70 years. 4. ECOG Performance Status (PS) of 0 or 1. 5. Assessed by a head and neck oncologist as resectable with no distant metastasis.

    6. At least one evaluable lesion according to RECIST v1.1. 7. Adequate organ function to tolerate surgery:

  • Hematology: WBC ≥ 4000/μL, ANC ≥ 2.000/μL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100,000/μL.

  • Liver function: Bilirubin ≤ 1.5× ULN, AST/ALT ≤ 3× ULN, ALP ≤ 3× ULN, Albumin ≥ 3 g/dL.

  • Renal function: Serum creatinine ≤ 1.5× ULN or Cockcroft-Gault creatinine clearance ≥ 60 mL/min.

    8. Signed informed consent and willingness to comply with study procedures.

Exclusion Criteria:

  • 1. History of severe hypersensitivity to other monoclonal antibodies or any component of PD-1 monoclonal antibodies.

    2. Known or suspected autoimmune diseases, including dementia and epilepsy. 3. Recurrent disease, distant metastasis, concurrent other malignancies, or assessed as unresectable.

    4. Coagulation abnormalities (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency, or receiving thrombolytic/anticoagulant therapy.

    5. Severe heart or lung disease; cardiac or pulmonary function below grade 3 (including grade 3).

    6. Laboratory test values within 7 days prior to enrollment not meeting the relevant standards.

    7. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibody targeting T-cell co-stimulation or checkpoint pathways).

    8. Comorbidities requiring long-term immunosuppressive therapy or systemic/local use of immunosuppressive doses of corticosteroids prior to enrollment.

    9. HIV positive; HBsAg positive with detectable HBV DNA (≥ 1000 cps/ml); positive blood screening for chronic hepatitis C (HCV antibody positive).

    10. Use of anti-tumor traditional Chinese herbal medicine within 4 weeks prior to randomization.

    11. Pregnant or lactating women.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Camrelizumab plus Chemotherapy

Patients receive neoadjuvant Camrelizumab (200 mg, IV, Day 1) combined with nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.

Andre navne:
  • SHR-1210

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Andre navne:
  • Albumin-bundet paclitaxel

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Andre navne:
  • CDDP
Aktiv komparator: Chemotherapy Alone

Patients receive neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Andre navne:
  • Albumin-bundet paclitaxel

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Andre navne:
  • CDDP

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
2-year Event-Free Survival (EFS) Rate
Tidsramme: 2 years from randomization

Event-Free Survival (EFS) is defined as the time from randomization to the first occurrence of any of the following events: disease progression that precludes surgery, local or distant recurrence, treatment termination due to toxicity or complications, or death from any cause. The rate at 2 years will be calculated.

2 years from randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
2-year Overall Survival (OS) Rate
Tidsramme: 2 years from randomization

The percentage of patients alive at 2 years from randomization. If the patient died within 2 years, it will be censored at the last known alive date.

2 years from randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2029

Studieafslutning (Anslået)

1. januar 2030

Datoer for studieregistrering

Først indsendt

14. november 2026

Først indsendt, der opfyldte QC-kriterier

14. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • B2024-782

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .